Immix Biopharma announced that the California Institute for Regenerative Medicine, or CIRM, has awarded Immix Biopharma cell therapy division Nexcella an $8M CLIN2 grant award to support clinical development of chimeric antigen receptor T-cell therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX:
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
- Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
- Immix Biopharma doses first patient in U.S. AL amyloidosis trial with NXC-201
- Immix Biopharma initiated with a Buy at H.C. Wainwright
- Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum